Form 4: Apogee Therapeutics Director Lisa Bollinger Reports Stock Option Grant

Director Lisa Bollinger reports the acquisition of stock options for 18,550 shares of Apogee Therapeutics common stock.

Summary

• Lisa Bollinger, a director of Apogee Therapeutics, Inc. (APGE), reported a transaction involving derivative securities.
• On May 28, 2024, Ms. Bollinger acquired stock options for 18,550 shares of Apogee Therapeutics common stock at an exercise price of $47.86.
• The options vest in three approximately equal annual installments beginning on the first anniversary of the grant date, contingent upon continued service to the Issuer.
• Following the reported transaction, Ms. Bollinger beneficially owns 18,550 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The document reflects a routine transaction (stock option grant) which is generally viewed neutrally to positively as it aligns director interests with shareholders.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule incentivizes continued service to the company.

Industry Context

This is a standard practice for incentivizing board members in publicly traded companies, particularly in the biotech industry.

Comparison to Industry Standards

• Stock option grants are a common form of compensation for directors in publicly traded companies, especially in the biotechnology sector.
• The vesting schedule of three years is also typical, aligning with industry norms for incentivizing long-term commitment.
• Comparable companies like BioNTech or Moderna also utilize stock options as part of their director compensation packages.

Stakeholder Impact

• The stock option grant aligns the director's interests with those of the shareholders, incentivizing them to work towards increasing shareholder value.

Key Dates